Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.

about

Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.

Item

http://www.wikidata.org/entity/Q40454277

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Salvage therapy in first relap ...... ulation with multiple myeloma.

@en

type

Item

label

Salvage therapy in first relap ...... ulation with multiple myeloma.

@en

prefLabel

Salvage therapy in first relap ...... ulation with multiple myeloma.

@en

P1476

Salvage therapy in first relap ...... ulation with multiple myeloma.

@en

P2093

Alessandra Larocca

http://www.w3.org/2001/XMLSchema#string

Laura Corvatta

http://www.w3.org/2001/XMLSchema#string

Laura Maracci

http://www.w3.org/2001/XMLSchema#string

Mario Boccadoro

http://www.w3.org/2001/XMLSchema#string

Pietro Leoni

http://www.w3.org/2001/XMLSchema#string

Rossella Troia

http://www.w3.org/2001/XMLSchema#string

Sara Bringhen

http://www.w3.org/2001/XMLSchema#string

Silvia Gentili

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

P304

289-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12834

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Offidani

Francesca Gay

P577

2016-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27893171

http://www.w3.org/2001/XMLSchema#string